Hepatotoxicity due to pemoline. Report of two cases.
Pemoline, a central nervous system stimulant, has been used extensively in Great Britain and Europe for a variety of conditions including memory failure and depression. In the 10 years that the drug has been used no report of hepatotoxicity has appeared. A prospective study of efficacy and safety of pemoline was started in the United States approximately 3 years ago. This report describes two patients who developed reversible liver abnormalities while receiving pemoline during the study and following rechallenge with the drug.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008569:Memory Disorders / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D008875:Middle Aged; D010389:Pemoline / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D012039:Regional Blood Flow / Q000187:drug effects; D013448:Sulfobromophthalein; D014481:United States
D013448:Sulfobromophthalein; D010389:Pemoline; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase